N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide

CAS NO.：726169-73-9
Empirical Formula: C23H20N6O
Molecular Weight: 396.44
MDL number: MFCD10565970
SAFETY DATA SHEET (SDS)
Update Date: 2026-07-14 16:49:18

What is N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide?

Description

Mocetinostat (726169-73-9) is a class I, isoform-selective HDAC inhibitor, IC50s=0.15, 0.29, 1.66 and 0.59 μM for HDAC1, 2, 3 and 11 respectively.1 Induces hyperacetylation of histones, induces expression of the tumor suppressor p21WAF1 and inhibits proliferation of human cancer cells.2 Mocetinostat displays antifibrotic effects in ischemic heart failure.3 Attenuates the development of hypersensitivity in models of neuropathic pain.4 Active in vivo.5

The Uses of N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide

Mocetinostat is a multi-targeted histone deacetylase inhibitor used in cancer therapy. Mocetinostat is undergoing clinical trials for the treatment of various cancers including follicular lymphoma, Hodgkin’s lymphoma and acute myelogenous leukemia.

What are the applications of Application

Mocetinostat is a potent inhibitor of HDAC1, HDAC2, HDAC3, and HDAC11

Definition

ChEBI: N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide is a member of benzamides.

References

1) Zhou et al. (2008), Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ulpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor; J. Med. Chem., 51 4072 2) Raeppel et al. (2009), SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4((4-(pyridine-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103); Bioorg. Med. Chem. Lett., 19 644 3) Nural-Guvener et al. (2015), Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure; Int. J. Mol. Sci., 16 11482 4) Denk et al. (2013), HDAC inhibitors attenuate the development of hypersensitivity in models of neuropathic pain; Pain, 154 1668 5) Bonfils et al. (2008), Evaluation of the pharmacodynamics effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay; Clin. Cancer Res., 14 3441

Properties of N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide

Melting point:	>170oC (dec.)
Density	1.340±0.06 g/cm3(Predicted)
storage temp.	RT
solubility	Soluble in DMSO (up to 25 mg/ml)
form	solid
pka	13.13±0.70(Predicted)
color	Off-white
Stability:	Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.

Safety information for N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide

Computed Descriptors for N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide

New Products

5-bromo-4-fluoro-2-nitrobenzaldehyde (R)-(-)-2-Amino-1-propanol Cyclobutanone Fmoc-OSu 1-(2-Chloroethyl)pyrrolidine Hydrochloride 2-Amino-2-(4-methylphenyl)acetic acid β-Bromostyrene Ethyl 3-phenylpropanoate Phenethyl cinnamate Dipropyl disulfide 4 pentyn 1 ol N-Vinylformamide Methacrylate-PEG-Methacrylate, Mn:35000 2,4-Dihydroxyacetophenone 2-Chloro 5-Fluoro Pyridine Vasicinone 2-Chloroisonicotinic Acid Tween 80 or Polysorbate 80 2-Butyn-1-oL 2-Pentyn-1-oL 4-Nitrobenzotrifluoride N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indol-3-yl)pyrimidin-2-amine Pirtobrutinib intd. N-(4-Cyano-3-(trifluoromethyl)phenyl)-2-methyloxirane-2-carboxamide

Related products of tetrahydrofuran

Entinostat

Belinostat (PXD101)

Vorinostat

JNJ-26481585

Panobinostat

ACY-1215

Acetanilide

Troglitazone